Advertisement
UK markets closed
  • FTSE 100

    8,433.76
    +52.41 (+0.63%)
     
  • FTSE 250

    20,645.38
    +114.08 (+0.56%)
     
  • AIM

    789.87
    +6.17 (+0.79%)
     
  • GBP/EUR

    1.1622
    +0.0011 (+0.09%)
     
  • GBP/USD

    1.2525
    +0.0001 (+0.01%)
     
  • Bitcoin GBP

    48,631.00
    -1,500.84 (-2.99%)
     
  • CMC Crypto 200

    1,259.40
    -98.61 (-7.26%)
     
  • S&P 500

    5,222.68
    +8.60 (+0.16%)
     
  • DOW

    39,512.84
    +125.08 (+0.32%)
     
  • CRUDE OIL

    78.20
    -1.06 (-1.34%)
     
  • GOLD FUTURES

    2,366.90
    +26.60 (+1.14%)
     
  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     
  • HANG SENG

    18,963.68
    +425.87 (+2.30%)
     
  • DAX

    18,772.85
    +86.25 (+0.46%)
     
  • CAC 40

    8,219.14
    +31.49 (+0.38%)
     

Will Oxford Biomedica's share price (LON:OXB) suffer because of its poor F-Score?

Healthcare operator Oxford Biomedica (LON:OXB) is a gene and cell therapy company that is engaged in lentiviral vector and cell therapy research, development and production. Breakthroughs in these fields can lead to fast growth for this type of company.

Unfortunately, so far, in its pursuit of profitability, Oxford Biomedica has racked up some pretty hefty losses:

5d79f441c712eimage.png
5d79f441c712eimage.png

The Piotroski F-Score distils a wealth of financial data relating to a company's financial health trend into one easily comparable score. I want to see what it says about Oxford Biomedica, given its history of losses.

GET MORE DATA-DRIVEN INSIGHTS INTO LON:OXB »

What the Piotroski F-Score says about Oxford Biomedica (LON:OXB)

The Piotroski F-Score is a nine-strong checklist split up into three sections, each looking at a different part of a company's financial situation. Unlike most ratios, the F-Score looks more deeply into the direction in which a company’s financial health is moving.

ADVERTISEMENT

Piotroski found that weak stocks with an F-Score of 2 or less are five times more likely to either go bankrupt or delist due to financial problems. Working our way through Piotroski's checklist, we can see that Oxford Biomedica gets a lowly F-Score of 2 out of a possible 9...

5d79f52cdc951image.png
5d79f52cdc951image.png


This means that not only is Oxford Biomedica (LON:OXB) financial health deteriorating, it currently fits in with the stocks that Piotroski identified as being five times more likely to go bankrupt or delist.

Fortify your portfolio with simple, effective tools

The problem areas for Oxford Biomedica identified here can be explored in more depth on Stockopedia's research platform. All the best investors have stringent due diligence processes that reduce the chances of them suffering big losses, so why not take a leaf out of their book?

Simple tools can help us better measure and understand the risks we take. That's why the Stockopedia team has been busy building new ways of understanding investment risks and company characteristics. In this webinar, we talk about two or our most popular innovations: StockRank Styles and RiskRatings. These indicators transform a ton of vital financial information into intuitive classifications, allowing you to get an instant feel for any company on any market - sign up for a free trial to see how your stocks stack up.